Pseudonymization

The European Unified Patient Identity Management (EUPID) tool was initially developed by the Austrian Institute of Technology (AIT) and is managed by the European Commission – Joint Research Centre (EC-JRC) 20. It was recommended by the European Rare Disease Registry Infrastructure (ERDRI) for rare disease research 21. EUPID is provided as a Software-as-a-Service (SaaS) and can be used in two ways. Users can access the web-based interface on the ERDRI platform, which allows to use tool directly in the browser, making it particularly accessible for non-technical users. Alternatively, it is possible to integrate it into other systems via https://africanownews.com/security-at-the-highest-level-eset-nod32-antivirus-review.html an API, which may require programming knowledge. The source code is not publicly available, so potential updates cannot be verified.

Encryption of Identifiers

• However, back to the essence as we don’t want to get too technical and added some additional information on all the mentioned terms below.
• Tokenisation is an efficient technique, and therefore it can be suitable for large-scale processing.
• Unlike EUPID, SPIDER is exclusively intended for research on rare diseases 36, 37.
• By applying these techniques appropriately, businesses can protect sensitive data, maintain compliance, and build trust with their customers.
• The first dimension, (1) single-center vs. multi-center, assesses whether a research activity takes place at a single or spans multiple sites.

Choose pseudonymisation when you need to maintain the ability to link data back to individuals in the future (for research follow-up, audit, or accountability purposes), or when complete anonymisation would destroy the data’s utility. Anonymisation under GDPR is the process of permanently and irreversibly modifying personal data so that no individual can be identified from the resulting dataset, directly or indirectly, by any means reasonably likely to be used. Truly anonymised data is no longer personal data and falls entirely outside the scope of GDPR.

Similar articles

The EDPB’s three tests must be satisfied for the full dataset before anonymisation can be claimed. There is no key that could reverse it.• The data controller itself must not be able to re-identify individuals.• Re-identification must not be possible through the combination with other reasonably available data sources. A cryptographic algorithm transforms identifiers into ciphertext using an encryption key. The encryption key must be stored separately from the encrypted data and subject to robust key management procedures.

Key Differences Between Anonymization and Pseudonymization

In conclusion, both pseudonymization and anonymization are effective methods for protecting PII, and the best method will depend on the specific use case and the level of privacy required. When in doubt, it’s always best to err on the side of caution and choose the method that provides the highest level of privacy protection. Pseudonymization is a recognized technique under GDPR for reducing compliance burdens, while anonymization helps organizations eliminate regulatory risks entirely. Companies must evaluate their data use cases, compliance needs, and security requirements before choosing a method. What was intended as a gift to the research community quickly became a cautionary tale.

• Take scientific research (which we mentioned earlier as an example) in healthcare, whereby data subjects are requested by their physician if they want to join the research program.
• One of the defining features of pseudonymization — as opposed to anonymization (more on that in a few) — is that it is reversible.
• Pseudonymization enables secure data sharing with specific third parties while retaining the ability to re-identify data if necessary.
• This was an early, analog form of pseudonymization.The true catalyst was the explosion of the internet and big data in the 1990s and 2000s.

In some regions, such as the United States, medical data is explicitly regulated under specific laws like the Health Insurance Portability and Accountability Act (HIPAA) 5. In contrast, in the European Union, medical data falls under the broader scope of personal information as defined by the General Data Protection Regulation (GDPR) 6. To address these challenges, methods are needed that protect privacy while collecting and managing such data 7. In future work, the STRIDE methodology 39 and ISO risk management processes 40 can be used to describe and analyze threats. As a starting point for showing that pseudonymization protects data adequately, we propose to utilize methodologies developed in the area of privacy-preserving data outsourcing.